Surgical Robotics Technology
MicroPort® CRM announces the launch in Europe of TALENTIA™ and ENERGYA™, their new range of Implantable Cardiac Defibrillators (ICDs) and Cardiac Resynchronization Therapy and Defibrillation devices (CRT-Ds), featuring Bluetooth®1 connectivity.
Simultaneously with the release of TALENTIA™ and ENERGYA™ ranges, MicroPort® CRM launches a new user interface dedicated to their ICDs and CRT-Ds. The very modern “look and feel” interface perfectly suits to their SmartTouch™ tablet programmer.
Benoît Clinchamps, President of MicroPort® CRM, stated: “These new Bluetooth-enabled ICDs and CRT-Ds, incorporating state-of-the-art technology and exceptional longevity, alongside a modern and user-friendly programmer interface, highlight MicroPort® CRM’s dedication to enhancing device connectivity and providing advanced patient care”.
The first implantation, a TALENTIA™ 4LV CRT-D SonR® system, was successfully completed by Doctor Fernando López, a cardiologist from the Arrhythmia Unit at Hospital Universitario Central de Asturias (HUCA), led by Doctor José Manuel Rubín, in Oviedo, Spain on Wednesday, April 17, 2024.
The team commented: “Since our participation in the RESPOND-CRT4 trial we have always trusted in SonR® technology to automatically optimize cardiac resynchronization parameters, at rest and during exercise. Now, with the new interface on the MicroPort® tablet programmer, we have in hands advanced tools for following-up our patients who have been implanted with their defibrillators. Furthermore, their devices ensure smooth patient care by transmitting device data effortlessly via the dedicated mobile remote monitor.”
TALENTIA™ and ENERGYA™ ranges enable wireless communication via Bluetooth®, allowing for tablet-based programming and remote monitoring. These devices also feature several advanced functionalities such as: the Lead Parameter Evaluation (LPE) algorithm, the new monitoring alert on defibrillation leads, PARAD+™ arrhythmia discrimination algorithm with the clinically proven lowest rate of inappropriate shocks2, and AutoMRI™, a function that automatically switches the device into a specific mode to protect patients during Magnetic Resonance Imaging (MRI) examinations3. These devices are also approved for 1.5 Tesla (T) and 3T MRI compatibility.
SonR®, a unique hemodynamic sensor measuring the contractility of the left ventricle is a MicroPort® exclusivity available on TALENTIA™ CRT-D SonR®. The SonR® system is the first and only CRT hemodynamic sensor designed to automatically optimize patients every week and, more importantly, while the patient is active, providing real-life optimization. The clinically proven SonR® algorithm has demonstrated a 35% risk reduction in heart failure hospitalization.4
In addition, MicroPort® CRM ICDs and CRT-Ds devices incorporate advanced technology with low current consumption, resulting in no compromise on the device longevity. TALENTIA™ and ENERGYA™ with the world’s greatest projected longevity make them the longest-lasting defibrillators on the market.5,6
References:
1. Bluetooth is a registered trademark of Bluetooth SIG, Inc
2. Dichtl W. et al., Low rates of inappropriate shocks in contemporary real-world implantable cardioverter defibrillator patients: the CARAT observational study. EP Europace, Volume 25, Issue 9, September 2023, euad186.
3. MicroPort CRM MRI Solutions Manuals available online at microportmanuals.com
4. Brugada J., et al. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. Eur. Heart J 2017; 38(10):730-8
5. Refer to user manual supplied with the device for complete instructions for use
6. Munawar DA et al. Predicted longevity of contemporary cardiac implantable electronic devices: A call for industry-wide “standardized” reporting. Heart Rhythm. 2018 Dec;15(12):1756-1763.
7. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–1853
Source: MicroPort
